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Abstract
Brain-derived neurotrophic factor (BDNF) is highly
expressed in the developing brain. It has anti-apoptotic
abilities, and protects the neonatal brain. In experimental
settings in adult animals, pre-treatment with nicotine has
shown increased BDNF levels, indicating a possible con-
tribution to nicotine’s anti-apoptotic effect. Apoptosis
contributes to the development of brain damage in peri-
natal asphyxia. We examined the effects of nicotine on
apoptosis-inducing factor (AIF), caspase-3 and BDNF in
the hippocampus of a neonatal piglet model of global
hypoxia. Forty-one anesthetized newborn piglets were
randomized to one of four groups receiving different
infusions after hypoxia (1) nicotine 130 mg/kg/h, 2) 260
mg/kg/h, 3) adrenaline, and 4) saline, all 2.6 mL/kg/h.
Four hours after hypoxia they were euthanized. The left
hemisphere/hippocampus was examined by histopathol-
ogy and immunohistochemistry; the right hippocampus
was analyzed using real time PCR. There was a signifi-
cantly higher expression of BDNF mRNA and protein in
the animals treated with nicotine 130 mg/kg/h vs. the
saline treated group (mRNA Ps0.038; protein Ps0.009).
There were no differences regarding AIF or caspase-3.
We conclude that nicotine (130 mg/kg/h), infused over 1
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h after global hypoxia in neonatal piglets, increases levels
of both BDNF mRNA and protein in the hippocampus.
This might imply neuroprotective effects of nicotine in
asphyxiated neonates.
Keywords: Apoptosis-inducing factor; brain-derived
neurotrophic factor; base excess; hippocampus,
nicotine.
Introduction
Worldwide, perinatal asphyxia has a substantial impact
on neonatal morbidity and mortality w4, 22x. Treatment
options are scarce, with therapeutic hypothermia being
the most promising intervention so far w25x. It has, how-
ever, not proven fully capable of preventing the second-
ary damage seen in perinatal asphyxia, and thus there is
still an ongoing search for interventional strategies. Eryth-
ropoietin and xenon-gas are examples of strategies that
are currently being studied w7, 23x. Another strategy that
has been investigated is the use of brain-derived neu-
rotrophic factor (BDNF). BDNF is highly expressed in the
developing brain, supporting the survival and mainte-
nance of specific populations of neurons both in the
peripheral and central nervous system w19, 24x. It has
anti-apoptotic abilities, blocking the activation of cas-
pase-3, and decreasing the up-regulation of other pro-
apoptotic proteins (phosphorylated c-Jun, cytochrome
C) when administered intracerebroventricular or intraoc-
ular in rats w11, 20x. BDNF does not cross the blood brain
barrier, and must thus be administered directly intra-
cerebrally w12x. This limits the use in clinical contexts.
Agents that increase levels of BDNF could, however, be
of use. Nicotine has been shown to have neuroprotective
abilities in animal and in vitro experiments w13, 28, 30,
31x. This has also been demonstrated in neonatal models
w3, 5, 18x. Nicotine acts both as an anti-inflammatory and
an anti-apoptotic agent w13, 26x, and has been found to
increase levels of the anti-apoptotic BDNF w8, 29x. Apop-
tosis is a major contributor to cell death in perinatal
asphyxia w4, 33x, and is executed via at least three path-
ways. One is caspase-independent and involves the
apoptosis-inducing factor (AIF). AIF can also induce cas-
pase-activation by triggering the release of mitochondrial
cytochrome C. The other two involve the intrinsic path-
way (apoptosome formation and caspase-9 cleavage)
and the extrinsic pathway (binding of the Fas-ligand to
554 Andresen et al., Nicotine increases BDNF in hippocampus
Article in press - uncorrected proof
its receptor and subsequent caspase-8 cleavage), both
leading to caspase-3 activation, a key executioner of
apoptosis w32, 34, 35x.
Nicotine effect on apoptosis and on BDNF has so far
not been demonstrated in neonatal hypoxic animal
models. We wished to examine the nicotine effects on
AIF, caspase-3 and BDNF in a well-established neonatal
piglet model of global hypoxia. We hypothesized that
nicotine in this setting would decrease the levels of AIF
and caspase-3 mRNA expression in the hippocampus;
increase the levels of BDNF mRNA-expression in the
hippocampus, and increase the levels of BDNF-protein
in the hippocampus measured by immunohistochemistry.
This would imply a possible neuroprotective effect of nic-
otine in hypoxic brain damage in the neonate.
Materials and methods
Approval
The Norwegian Council for Animal Research approved the
experimental protocol. The animals were cared for and handled
in accordance with the European Guidelines for Use of Experi-
mental Animals, by certified FELASA (Federation of European
Laboratory Animals Science Associations) category C
researchers.
Surgical preparation and anesthesia
Forty-one Noroc (LYxLD) pigs were included in the study, inclu-
sion criteria being age of 12–36 h, hemoglobin values )5 g/dL,
and good general condition. Anesthesia was induced by Sevo-
flurane 5% (Sevorane, Abbott), reduced to 2% before an ear vein
was cannulated, Sevoflurane was disconnected, and the piglets
were given pentobarbital sodium 20 mg/kg and Fentanyl 50 mg/kg
intravenously as bolus injections. Anesthesia was maintained by
a continuous infusion of Fentanyl (50 mg/kg/h) and Midazolam
(0.25 mg/kg/h; IVAC P2000 infusion pump). When necessary, a
bolus of Fentanyl (10 mg/kg) or Midazolam (1 mg/kg) was added.
When shivering occurred that did not cease with additional
anesthetics, the animals were given pancuronium bromide
(0.1 mg/kg). A continuous i.v. infusion (saline 0.7% and glucose
1.25%, 10 mL/kg/h) was given throughout the experiment. The
animals were surgically prepared with tracheotomy and insertion
of femoral catheters, and ventilated as described in a previous
study w3x. Rectal temperature was maintained between 38.5 and
408C with a heating blanket and a radiant heating lamp. Mean
arterial blood pressure (MABP) was measured continuously in
the left femoral artery using BioPac systems MP150-CE.
Experimental protocol
All the animals were subjected to global hypoxia after a stabili-
zation period of 90 min. The global hypoxia was induced by 8%
O2 in N2 until base excess (BE) Fy20 mmol/L or MABPs15 mm
Hg. At the end of hypoxia the animals were randomized to one
of four groups with different infusions given over 1 h. Animals of
both genders were used, and we aimed at a 50/50 distribution
in the different groups. The groups were as follows: 1. Nicotine
(nicotine hydrogen tartrate, Sigma-Aldrich, Oslo, Norway)
130 mg/kg/h (ns13); 2. Nicotine 260 mg/kg/h (ns10); 3. Saline
(ns9); 4. Adrenaline 0.05 mg/kg/minqsaline (ns9). All infusions
were given in the dose of 2.6 mL/kg/h and started 5 min after
the end of hypoxia. All infusions were given separately in a cen-
tral venous line. Other drugs and fluids were given through a
peripheral line for the duration of the infusion. After the infusions
were ended, the animals were observed for 3 h, and were there-
after given an overdose of 150 mg/kg pentobarbital intrave-
nously. The rationale for giving the different groups the
mentioned infusions was as follows: nicotine 130 mg/kg/h has
been used previously with effect w1x, nicotine 260 mg/kg/h was
chosen to assess if it was too high to have an effect, or if a
higher dose than 130 mg/kg/h would give an even better effect.
Adrenaline was given in a dose that mimics the starting dose for
hypotensive neonates in the intensive care units; this group was
added to imitate nicotine effect on the sympathetic nervous sys-
tem, to assess the impact of this effect on nicotine neuropro-
tective abilities. The saline treated group was the control group.
Blood sampling
Hemoglobin was measured on a HemoCue Hb 201q(HemoCue
AB, Angelholm, Sweden) at baseline. Temperature-corrected
arterial acid/base status and glucose were measured regularly
with a Blood Gas Analyzer 860 (Ciba Corning Diagnostics, Mid-
field, MA), the blood being obtained from the femoral artery
catheter. Two mL of blood for analyses of nicotine concentra-
tions were drawn after the infusion was ended, and frozen at
–708C until analyzed as previously described w2x. All drawn
blood was immediately replaced with saline 1.5 times the
volume removed.
Tissue sampling
The brain was immediately removed after the overdose had
been administered, and the left hemisphere and the cerebellum
were placed in 4% buffered formalin at a temperature of 48C.
The posterior part of the right hippocampus was immersed in
RNASafer (Stabilizer reagent, Omega Bio-tek Inc., Norcross
GA, USA) and frozen at –708C for later real-time PCR analyses
of BDNF, AIF and caspase-3 gene expression.
Real-time polymerase chain reaction (real-time PCR)
The hippocampus samples were homogenized using MagNA
Lyser Green Beads tubes (Roche Diagnostics GmbH, Mann-
heim, Germany) and lysis buffer. Total RNA from the supernatant
was prepared using a Total RNA Kit from E.Z.N.A., and treated
with DNase I (E.Z.N.A. Total RNA Kit, Omega Bio-tek). Extracted
total RNA was quantified using an ND-1000 spectrophotometer
(NanoDrop Technologies, Inc., USA). Total RNA (2–3 mg) was
reverse transcribed into cDNA employing the High Capacity
cDNA Archive Kit (Applied Biosystems Inc.) in a GeneAmp PCR
System 9700 thermal cycle according to the manufacturer’s
protocol. Real-time PCR was performed with 20 ng cDNA for
the target genes and housekeeping gene (PPIA), employing the
SYBR Green PCR Master mix in an ABI PRISM 7000 Sequence
Detection System in a universal instrument setting. The following
primers and primer concentrations were used: (BDNF:
59AGCGTGTGCGACAGCATTAG (sense), 59GTCCACTGCCGT-
CTTTTTATCC (antisense); AIF: 5’AGGACTCCTTCCATCACAAT-
GTG (sense), 59TTGGCAAACCCCCTTTCC (antisense); caspase-3:
59AGCGCTGAAACAGTATGTTCACA (sense), 59TTCTACTGC-
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Table 1 Grading of damage in striatum, hippocampus, cortex
and cerebellum.
Grade Degree of damage
Striatum, hippocampus and cortex
0 No necrosis
1 F10% of tissue necrotic
2 20–30% of tissue necrotic
3 40–60% of tissue necrotic
4 )75% of tissue necrotic
Cerebellum
0 No eosinophilic Purkinje cells
1 -50 eosinophilic Purkinje cells
2 50–150 eosinophilic Purkinje cells
3 )150 eosinophilic Purkinje cells
Figure 1 Relative expression of BDNF mRNA in hippocampus.
The group treated with nicotine 130 mg/kg/h show a significant
increase in BDNF mRNA expression compared to the group
treated with saline.
1snicotine 130 mg/kg/h; 2snicotine 260 mg/kg/h; 3sadrena-
line 0.05 mg/kg/minqsaline; 4ssaline. *Ps0.038 for nicotine
130 mg/kg/h vs. saline.
TACCTTTCGGTTAACC (antisense); PPIA: 59ATA CGG GTC CTG
GCA TCT TG (sense); 59AAC TGG GAA CCG TTT GTG
(antisense).
Real-time PCR quantification of nucleic acids was done by
employing the comparative CT method of relative quantification
(RQ). RQ was calculated for each group using DCt (normalized
to the endogenous control). The arithmetic formula 2 –DCt was
used for the values displayed in Figure 1.
Pathological examination
Fixation and staining Tissue blocks (0.5 cm thick) from stria-
tum, hippocampus, cortex and cerebellum were embedded in
paraffin, sliced in 4 mm thick sections and stained with hema-
toxylin and eosin (H&E).
Immunohistochemistry Immunohistochemistry with MAP-2
(microtubule-associated protein 2) was performed as previously
described w1x. For BDNF the formalin-fixed paraffin-embedded
sections were deparaffinized, rehydrated and demasked in a
microwave oven for 25 min in TRIS/EDTA buffer at pH 9.1.
Monoclonal anti-human BDNF antibody titer 1:25 (Clone 35928;
R&D Systems, Minneapolis, MN, USA) was used as primary
antibody. This antibody has previously been found to have 100%
sequence homology to the porcine antibody w24x. The antigen-
antibody reaction was visualized with DakoCytomation En-
Visionq System-HRP (K4007; Dako, Carpinteria, CA, USA),
using 3.39-diaminobenzidin as the chromogen. The sections
were counterstained with hematoxylin.
Evaluation of histopathology The samples were evaluated by
a pathologist who was blinded to the randomization, and only
had the numbers of the animals as ID. Areas with vacuolated
neuropil, shrunken neurons with pyknotic nuclei and scattered
eosinophilic neurons, were defined as necrosis. MAP-2, which
is a sensitive marker for neuronal ischemic injury w14x, was used
to confirm the areas of damage. There was a good correlation
between the morphologic changes in the HE-stained sections
and loss of MAP-2 staining. Vacuolated areas in subcortical
white matter damage were assessed as necrosis, graded as
either present or non-present. Necrosis in striatum, hippocam-
pus and cortex was divided into five different categories as
shown in Table 1. For the cerebellum, the hypoxic/ischemic
changes were defined by the presence of necrotic Purkinje cells
with eosinophilic cytoplasm. In each case the number of eosino-
philic Purkinje cells was counted in one section from the vermis
of the cerebellum. Damage was classified as shown in Table 1.
Evaluation of BDNF immunohistochemistry Gyrus dentatus
was chosen as the area to evaluate, due to the fact that this is
the area of most BDNF-protein according to Kokaia et al. w16x.
Positive neurons were identified as staining a dark brown color,
while negative neurons had a blue or light brown coloring similar
to background staining. We counted positive and negative cells
in three areas at 40=enlargement, and calculated the percent-
age of positive neurons for further analyses (positive cells divid-
ed through the total number of cells). We only colored the
hippocampi of the animals from the groups treated with 130
mg/kg/h and saline, choosing these two groups since they were
the most interesting to compare. The evaluations were done
blinded.
Statistical analysis
Statistical analyses were performed by SPSS version 15 (SPSS
Inc., Chicago, IL, USA). All values are presented as mean"SD.
Weight, age, Hb, time of endured hypoxia and real-time PCR
results were calculated using one-way ANOVA with post hoc
tests where appropriate. Immunohistochemistry results were
calculated using Student’s t-test. All analyses for repeated
measures were done using multivariate GLM (general linear
model) with post hoc tests where appropriate. Histopathological
findings were calculated using ordinal regression, for white mat-




The mean age of the animals was 27 ("3) h, weight 1970
("140) g, hemoglobin was 7.5 ("1) g/dL, and the time
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Table 2 Physiological data.
Nicotine 130 mg/kg/h Nicotine 260 mg/kg/h Saline Adrenaline
ns13 ns10 ns9 ns9
MABP (mm Hg)
B 66"9 68"14 74"18 73"13
EH 26"8 23"7 24"6 27"7
EI 51"14 42"10* 48"6 53"8*
EE 54"16§ 40"7**§ 38"9 51"13**
B 2"2.9 3"3.3 1"3.1 3"3.6
BE (mmol/L)
EH –20"2.5 –20"1.8 –21"0.6 –20"1.9
EI –5"4.3 –7"2.3 –7"2.4 –7"1.7
EE 0"4.2 –1"3.5 –5"6.0 –1"1.8
pH
B 7.44"0.04 7.45"0.05 7.43"0.06 7.45"0.05
EH 7.06"0.05 7.06"0.04 7.05"0.04 7.07"0.05
EI 7.33"0.08 7.30"0.03 7.30"0.04 7.32"0.04
EE 7.40"0.08 7.40"0.05 7.32"0.09 7.39"0.03
pCO2 (kPa)
B 5.1"0.2 5.2"0.5 5.2"0.4 5.3"0.6
EH 4.7"0.4 5.0"0.5 4.7"0.9 4.7"0.4
EI 5.2"0.5 5.4"0.3 5.2"0.4 5.0"0.3
EE 5.3"0.4 5.1"0.5 5.7"0.3 5.3"0.3
pO2 (kPa)
B 12.5"1.9 12.0"1.5 12.6"1.2 13.3"3.6
EH 4.5"0.3 4.3"0.5 5.0"1.1 4.9"1.0
EI 11.4"1.6 10.7"1.2 11.8"1.3 11.0"0.7
EE 12.1"1.9 11.1"2.1 12.0"1.5 11.3"0.6
Temp (8C)
B 39.7"0.2 39.6"0.2 39.4"0.2 39.5"0.2
EH 39.2"0.2 39.3"0.2 39.1"0.3 39.3"0.2
EI 39.6"0.3 39.6"0.2 39.7"0.2 39.7"0.2
EE 39.2"0.2 39.2"0.3 39.2"0.3 39.2"0.3
Blood-glucose (g/dL)
B 6.2"1.0 6.1"1.0 6.7"1.0 6.3"0.7
EH 11.9"9.1 8.7"4.3 10.6"2.1 9.6"3.4
EI 8.2"3.1 7.7"4.0 8.9"3.1 7.8"2.8
EE 6.1"2.3 7.3"2.7 7.7"2.7 6.0"1.1
Physiological data at four different time points throughout the experiment.
*,**indicates significant difference for nicotine 260 mg/kg/h vs. adrenaline (*Ps0.018, **Ps0.043).
§Indicates significant difference for nicotine 260 mg/kg/h vs. nicotine 130 mg/kg/h (Ps0.009).
B, baseline; BE, base excess; EH, end hypoxia; EI, end infusion; EE, end experiment.
the animals endured hypoxia was on average 62 ("24)
min, median time being 58 min (range 30–150). There
were no significant differences between the groups
regarding these parameters. A total of 22 of the 41 ani-
mals were male, with the following gender distribution
within the groups: nicotine 130 mg/kg/h 7/13 male; nico-
tine 260 mg/kg/h 5/10 male; saline 5/9 male; adrenaline
5/9 male. There was a significant difference between
nicotine 260 mg/kg/h and adrenaline regarding MABP at
the end of the infusion (42"10 vs. 53"8 mm Hg;
Ps0.018) and at the end of the experiment (40"7 vs.
51"13 mm Hg; Ps0.043); and there was also a signifi-
cant difference regarding MABP for nicotine 260
mg/kg/h vs. nicotine 130 mg/kg/h at the end of the exper-
iment (40"7 vs. 54"16 mm Hg; Ps0.009). pCO2, pO2,
BE, pH, temperature and blood glucose showed no sig-
nificant differences between the groups (Table 2). In all
but three of the animals hypoxia was ended due to a
decrease in BE (i.e., in 93% of the cases). As shown in
Table 2 there were no significant differences between the
groups regarding BE and MABP at the end of hypoxia.
Nicotine concentrations The groups treated with
saline or adrenaline had nicotine concentrations in full
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Figure 3 Immunohistochemistry of BDNF protein.
Picture from the dentate gyrus 40=enlarged. The cells with the
large, dark brown nucleuses are positive (black arrows), the cells
with light brown or blue nucleuses are negative (open arrows).
Figure 2 Box plot of % BDNF positive cells in the dentate
gyrus of the hippocampus.
There are significantly more BDNF positive cells in the dentate
gyrus of the animals treated with nicotine 130 mg/kg/h com-
pared to the saline treated animals. *Ps0.009.
Figure 4 Immunohistochemistry of BDNF protein, nicotine vs.
saline.
Pictures from the dentate gyrus 20=enlarged. A is from an ani-
mal treated with nicotine 130 mg/kg/h; B is from an animal treat-
ed with saline; picture A presents a larger number of BDNF
positive cells than picture B.
blood of 0 ng/mL, the group treated with 130 mg/kg/h:
64"21 ng/mL, and the group treated with 260 mg/kg/h:
135"35 ng/mL (P-0.001).
Real-time PCR of BDNF, caspase-3 and AIF
The relative expression of BNDF mRNA showed a sig-
nificant up-regulation in the hippocampus for the group
treated with nicotine 130 mg/kg/h compared to the saline
treated group (Ps0.038, Figure 1). For caspase-3 and
AIF, the real-time PCR measurements of the relative
expression of mRNA in hippocampus presented no sig-
nificant differences between the groups. We also did cal-
culations for the two genders separately, but this did not
present any significant findings.
BDNF immunohistochemistry
As mentioned, we only assessed the group treated with
nicotine 130 mg/kg/h and the group treated with saline.
We found a significant difference between the groups,
with the group treated with nicotine 130 mg/kg/h pre-
senting 33% ("14) positive cells, and the saline group
presenting 17% ("8) (Ps0.009, Figures 2–4).
Histopathology and MAP-2 in striatum,
hippocampus, cortex, cerebellum and
subcortical white matter
The damage in the striatum and cortex varied from no
damage to 40–60% of the tissue damaged; there were
no significant differences between the groups. However,
in the striatum there was a tendency towards less dam-
age in the group treated with nicotine 130 mg/kg/h with
2/13 (one -10% and one 20–40% damage) vs. 3/9 (one
-10% and two 40–60% damage) animals in the saline
group, as illustrated in Figure 5. MAP-2 confirmed the
findings. In hippocampus six animals presented damage
between 20% and 60%, these were the same animals
that presented more severe damage in the cortex and
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Figure 5 Scatter plot of histopathological damage in hippocampus and striatum.
The trend towards less damage in the group treated with nicotine 130 mg/kg/h is illustrated in these scatter plots. 1snicotine 130
mg/kg/h; 2snicotine 260 mg/kg/h; 3sadrenaline 0.05 mg/kg/minqsaline; 4ssaline.
striatum as well. The remaining animals had no damage
in the hippocampus, and there were no significant differ-
ences between the groups. As illustrated in Figure 5 there
was, however, a tendency towards less damage in the
group treated with nicotine 130 mg/kg/h, with 1/13
(20–30% damage) vs. 2/9 (both 40–60% damage) ani-
mals in the saline group. For the cerebellum all the three
categories of damage were present (Table 1), but none
of the cases with the most severe damage were seen in
the animals treated with low dose of nicotine or adren-
aline. Subcortical white matter damage was seen in a
total of 12 animals. This did not necessarily occur togeth-
er with necrosis in other areas. There were no significant
differences between the groups. There was no difference
between the animals presenting white matter damage
and the other animals regarding acidosis, MABP, or dura-
tion of endured hypoxia.
Discussion
In this study we show that nicotine in a low dose increas-
es BDNF in the hippocampus in a neonatal model of
hypoxic brain damage. This finding is in accordance with
findings in adult animal models, suggesting neuroprotec-
tive effects in the neonatal cohort.
It is unfortunate that the immunohistochemistry was
not conducted on all the animals. We do, however,
believe our results to be representative even without the
two other groups, and the results are in concordance
with the findings on mRNA.
We failed to show any effect of nicotine on apoptosis
in this study. There were no differences between the
groups regarding mRNA expression of AIF or caspase-3.
This could be due to a lack of effect of nicotine on both
the caspase-dependent and -independent pathways, but
it could also be due to the short observation period.
Nicotine has been shown to have an effect on apoptosis/
caspase-3 in vitro w9, 13x. Garrido et al. showed a max-
imal effect on caspase-3 after 12 h, with no statistical
difference between the groups at 3 h w9x. Immunohisto-
chemical staining with caspase-3 and TUNEL could have
been beneficial for the evaluation of apoptosis in our
study, but this was not done due to the short observation
time. It has been shown that there is a distinct difference
between genders regarding apoptosis and pathways
w27x, and gender should, therefore, be taken into account
when evaluating apoptosis. Renolleau et al. w27x
reviewed experiments in neonatal rodents and cell cul-
tures, presenting evidence that the male population
predominantly activates the AIF-dependent pathway,
whereas the female population presents a stronger acti-
vation of caspase-3. We included both genders in our
study, aiming at an equal distribution in the groups. When
we subdivided the groups into genders we did not find
any significant differences, but the groups were small and
thus not statistically reliable. We believe it is not possible
to draw any conclusions regarding nicotine effects on
apoptosis in our model until more research has been
conducted.
Regarding the histopathological findings, there were no
statistical significant differences between the groups in
any of the investigated regions. We do, however, find a
trend towards less injury in striatum and hippocampus in
the animals treated with the low dose of nicotine com-
pared to the control group. To properly assess the effect
of intervention after hypoxia-ischemia on histopatholog-
ical outcome, survival studies are necessary. This was
not possible with our current model.
We found a significant difference in MABP between the
higher dose of nicotine and the lower dose at the end of
the experiment, and between the higher dose of nicotine
and adrenaline after the infusion and at the end of the
experiment. The higher dose of nicotine failed to present
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a significant effect on BDNF mRNA, although Figure 1
shows a better effect in this group than in the saline and
the adrenaline groups. One could speculate if the lower
MABP could have caused the lack of effect on BDNF
mRNA. The group treated with adrenaline, however, did
not show any beneficial effects of a higher MABP, and it
is thus likely that MABP is not important for the effects
on BDNF mRNA. Nicotine is known to activate the
sympathetic nervous system in a dose-dependent man-
ner, but we have previously demonstrated that the doses
used in the current study do not increase plasma cate-
cholamines w2x. The difference in effect between the two
nicotine doses can thus not be explained by the differ-
ence in MABP – and one can speculate if the higher dose
might be too high to have a beneficial effect.
BDNF treatment has been shown to be beneficial in
animal models of hypoxia, presenting anti-apoptotic
effects w11x. Cheng et al. present an age-dependent neu-
roprotection with improved effect in rats at postnatal
day 7 compared to adult animals w6x. Kokaia et al. find
regional differences in the response of BDNF to hypoxia-
ischemia in the hippocampus, with gyrus dentatus and
CA3 as areas that present high levels of BDNF at base-
line and a significant increase after hypoxia-ischemia
w16x. Unpublished results from our laboratory show that
BDNF increases after hypoxia-ischemia in the current
model, and this is in accord with findings of asphyxiated
newborns presenting increased levels of BDNF in CSF
w17x. Regarding nicotine and neurotrophic factors, French
et al. w8x presented a significant increase in the nerve
growth factor (NGF), and a trend towards an increase in
BDNF after administration of nicotine locally in the hip-
pocampus. They also present an increase in TrkB, the
corresponding receptor to BDNF, which is also believed
to have antiapoptotic abilities. Garrido et al. w10x found
that nicotine pre-treatment before exposure of spinal
cord neurons to arachidonic acid protected against
decrease in BDNF levels. Kenny et al. w15x, however,
found a decrease in BDNF in rat hippocampus after an
acute administration of nicotine, and an increase after
chronic administration. Their study looks at adult ani-
mals, and administers nicotine at a relatively high dose
of 0.5 mg/kg. They claim that the acute dose has inhib-
itory effects, and that when given chronically tolerance
develops towards the inhibitory effects of nicotine on
BDNF. One could speculate if the mentioned inhibitory
effect is due to the dose – and that a smaller dose would
not have had the same effect.
It could be discussed if the increase in BDNF is a result
of increased injury, with BDNF being produced to coun-
teract the damage inflicted. We do, however, see a trend
towards less damage in the hippocampus in the animals
treated with a low dose of nicotine, supporting the
hypothesis that the nicotine induced increase in BDNF
has neuroprotective potential. The mechanisms behind
nicotine’s induction of BDNF release are not fully under-
stood, but Maggio et al. w21x speculate that it might be
a combination of nAChR activation and dopamine
release. Serres et al. w29x find that the a7 nAChR subunit
might be largely responsible for the increased secretion
of BDNF that is seen after nicotine administration in a
neuroblastoma cell line.
Nicotine as a neuroprotective agent is well-investigat-
ed in adult animal models, but it is a relatively new
approach in neonatal medicine. Two groups have looked
at nicotine in neonatal rodents – finding protective effects
w5, 18x. Laudenbach et al. did, however, find differences
in the activation of nAChR subtypes, claiming that the
effects in neonates is mediated via different mechanisms
than in adults w18x. This warrants more research on the
mechanisms by which nicotine exerts its neuroprotective
effects in neonatal models.
Weaknesses of the model used in this study are for
one the age of the animals; at 12–36 h of age the pigs
have already to some extent adapted to extra-uterine life,
and the lack of hypercapnia during global hypoxia. These
weaknesses limit the comparability with the clinical sit-
uation, and the results can hence not be directly trans-
ferred to the asphyxiated neonate.
Treatment of asphyxiated neonates is currently not
optimal. There is a need for better strategies to attenuate
the damage inflicted. A neuroprotective treatment should
be effective, easily administered, cost-effective, and
effective when given after delivery. Nicotine could be a
useful strategy, but further research must be conducted
on dose-response, and on finding the optimal dose and
duration of treatment. We have previously shown a sig-
nificant effect on cortical non-protein bound iron and
striatal glutamate 2 h after hypoxia (1 h after end of infu-
sion of nicotine) w3x, and speculate that a longer duration
of treatment might be beneficial.
In conclusion, we find that an infusion with nicotine
130 mg/kg/h for 1 h after global hypoxia in neonatal pig-
lets increases levels of both mRNA BDNF, and of BDNF
protein in the hippocampus. This might imply neuropro-
tective effects of nicotine in asphyxiated neonates.
Acknowledgements
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